Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report

BO. Wolthers, TL. Frandsen, CJ. Patel, R. Abaji, A. Attarbaschi, S. Barzilai, A. Colombini, G. Escherich, M. Grosjean, M. Krajinovic, E. Larsen, DC. Liang, A. Möricke, KK. Rasmussen, S. Samarasinghe, LB. Silverman, IM. van der Sluis, M. Stanulla,...

. 2019 ; 104 (3) : 556-563. [pub] 20181122

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20022858

Grantová podpora
R00 ES023504 NIEHS NIH HHS - United States
R21 ES025052 NIEHS NIH HHS - United States

Asparaginase-associated pancreatitis is a life-threatening toxicity to childhood acute lymphoblastic leukemia treatment. To elucidate genetic predisposition and asparaginase-associated pancreatitis pathogenesis, ten trial groups contributed remission samples from patients aged 1.0-17.9 years treated for acute lymphoblastic leukemia between 2000 and 2016. Cases (n=244) were defined by the presence of at least two of the following criteria: (i) abdominal pain; (ii) levels of pancreatic enzymes ≥3 × upper normal limit; and (iii) imaging compatible with pancreatitis. Controls (n=1320) completed intended asparaginase therapy, with 78% receiving ≥8 injections of pegylated-asparaginase, without developing asparaginase-associated pancreatitis. rs62228256 on 20q13.2 showed the strongest association with the development of asparaginase-associated pancreatitis (odds ratio=3.75; P=5.2×10-8). Moreover, rs13228878 (OR=0.61; P=7.1×10-6) and rs10273639 (OR=0.62; P=1.1×10-5) on 7q34 showed significant association with the risk of asparaginase-associated pancreatitis. A Dana Farber Cancer Institute ALL Consortium cohort consisting of patients treated on protocols between 1987 and 2004 (controls=285, cases=33), and the Children's Oncology Group AALL0232 cohort (controls=2653, cases=76) were available as replication cohorts for the 20q13.2 and 7q34 variants, respectively. While rs62228256 was not validated as a risk factor (P=0.77), both rs13228878 (P=0.03) and rs10273639 (P=0.04) were. rs13228878 and rs10273639 are in high linkage disequilibrium (r2=0.94) and associated with elevated expression of the PRSS1 gene, which encodes for trypsinogen, and are known risk variants for alcohol-associated and sporadic pancreatitis in adults. Intra-pancreatic trypsinogen cleavage to proteolytic trypsin induces autodigestion and pancreatitis. In conclusion, this study finds a shared genetic predisposition between asparaginase-associated pancreatitis and non-asparaginase-associated pancreatitis, and targeting the trypsinogen activation pathway may enable identification of effective interventions for asparaginase-associated pancreatitis.

Center for Biological Sequence Analysis Technical University of Denmark Lyngby Denmark

Center for Biological Sequence Analysis Technical University of Denmark Lyngby Denmark Molecular Neurogenetics Unit Psychiatric and Neurodevelopmental Genetics Unit Center for Genomic Medicine Massachusetts General Hospital Boston MA USA

Christian Albrechts University Kiel and University Medical Center Schleswig Holstein Department of Pediatrics Kiel Germany

CHU Sainte Justine Research Center and Department of Pharmacology University of Montreal QC Canada

CHU Sainte Justine Research Center and Department of Pharmacology University of Montreal QC Canada Department of Pediatrics University of Montreal QC Canada

Department of Biomedical Informatics Harvard Medical School Boston MA USA

Department of Pediatric Hematology and Oncology Hannover Medical School Germany

Department of Pediatric Hematology and Oncology St Anna Children's Hospital and Department of Pediatric and Adolescent Medicine Medical University of Vienna Austria

Department of Pediatric Oncology Dana Farber Cancer Institute and Division of Hematology Oncology Boston Children's Hospital Boston MA USA

Department of Pediatrics and Adolescent Medicine University Hospital Rigshospitalet Copenhagen Denmark

Department of Pediatrics and Adolescent Medicine University Hospital Rigshospitalet Copenhagen Denmark Institute of Clinical Medicine University of Copenhagen Denmark

Department of Pediatrics Ospedale San Gerardo University of Milano Bicocca Fondazione MBBM Monza Italy

Division of Pediatric Hematology Oncology Mackay Memorial Hospital Taipei Taiwan

Dutch Childhood Oncology Group The Hague and Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands

Great Ormond Street Hospital for Children London UK

Maine Children's Cancer Program Scarborough ME USA

Pediatric Hematology and Oncology Schneider Children's Medical Center of Israel Petah Tikva Israel and Sackler Faculty of Medicine Tel Aviv University Israel

St Jude Children's Research Hospital Department of Pharmaceutical Sciences Memphis TN USA

University Hospital Motol Department of Pediatric Hematology Oncology Prague Czech Republic

University Medical Center Eppendorf Clinic of Pediatric Hematology and Oncology Hamburg Germany

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20022858
003      
CZ-PrNML
005      
20201214124903.0
007      
ta
008      
201125s2019 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2018.199356 $2 doi
035    __
$a (PubMed)30467200
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Wolthers, Benjamin O $u Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark.
245    10
$a Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report / $c BO. Wolthers, TL. Frandsen, CJ. Patel, R. Abaji, A. Attarbaschi, S. Barzilai, A. Colombini, G. Escherich, M. Grosjean, M. Krajinovic, E. Larsen, DC. Liang, A. Möricke, KK. Rasmussen, S. Samarasinghe, LB. Silverman, IM. van der Sluis, M. Stanulla, M. Tulstrup, R. Yadav, W. Yang, E. Zapotocka, R. Gupta, K. Schmiegelow, Ponte di Legno toxicity working group,
520    9_
$a Asparaginase-associated pancreatitis is a life-threatening toxicity to childhood acute lymphoblastic leukemia treatment. To elucidate genetic predisposition and asparaginase-associated pancreatitis pathogenesis, ten trial groups contributed remission samples from patients aged 1.0-17.9 years treated for acute lymphoblastic leukemia between 2000 and 2016. Cases (n=244) were defined by the presence of at least two of the following criteria: (i) abdominal pain; (ii) levels of pancreatic enzymes ≥3 × upper normal limit; and (iii) imaging compatible with pancreatitis. Controls (n=1320) completed intended asparaginase therapy, with 78% receiving ≥8 injections of pegylated-asparaginase, without developing asparaginase-associated pancreatitis. rs62228256 on 20q13.2 showed the strongest association with the development of asparaginase-associated pancreatitis (odds ratio=3.75; P=5.2×10-8). Moreover, rs13228878 (OR=0.61; P=7.1×10-6) and rs10273639 (OR=0.62; P=1.1×10-5) on 7q34 showed significant association with the risk of asparaginase-associated pancreatitis. A Dana Farber Cancer Institute ALL Consortium cohort consisting of patients treated on protocols between 1987 and 2004 (controls=285, cases=33), and the Children's Oncology Group AALL0232 cohort (controls=2653, cases=76) were available as replication cohorts for the 20q13.2 and 7q34 variants, respectively. While rs62228256 was not validated as a risk factor (P=0.77), both rs13228878 (P=0.03) and rs10273639 (P=0.04) were. rs13228878 and rs10273639 are in high linkage disequilibrium (r2=0.94) and associated with elevated expression of the PRSS1 gene, which encodes for trypsinogen, and are known risk variants for alcohol-associated and sporadic pancreatitis in adults. Intra-pancreatic trypsinogen cleavage to proteolytic trypsin induces autodigestion and pancreatitis. In conclusion, this study finds a shared genetic predisposition between asparaginase-associated pancreatitis and non-asparaginase-associated pancreatitis, and targeting the trypsinogen activation pathway may enable identification of effective interventions for asparaginase-associated pancreatitis.
650    _2
$a mladiství $7 D000293
650    _2
$a alely $7 D000483
650    _2
$a protinádorové látky $x aplikace a dávkování $x škodlivé účinky $7 D000970
650    _2
$a asparaginasa $x aplikace a dávkování $x škodlivé účinky $7 D001215
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetické asociační studie $7 D056726
650    _2
$a genetická predispozice k nemoci $7 D020022
650    12
$a genetická variace $7 D014644
650    _2
$a genotyp $7 D005838
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a biologické modely $7 D008954
650    _2
$a pankreatitida $x etiologie $7 D010195
650    _2
$a fenotyp $7 D010641
650    _2
$a polyethylenglykoly $x aplikace a dávkování $x škodlivé účinky $7 D011092
650    _2
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a akutní lymfatická leukemie $x komplikace $x farmakoterapie $x genetika $7 D054198
650    _2
$a trypsin $x genetika $7 D014357
650    _2
$a trypsinogen $x genetika $7 D014362
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Frandsen, Thomas L $u Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark.
700    1_
$a Patel, Chirag J $u Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
700    1_
$a Abaji, Rachid $u CHU Sainte-Justine Research Center and Department of Pharmacology, University of Montreal, QC, Canada.
700    1_
$a Attarbaschi, Andishe $u Department of Pediatric Hematology and Oncology, St Anna Children's Hospital and Department of Pediatric and Adolescent Medicine, Medical University of Vienna, Austria.
700    1_
$a Barzilai, Shlomit $u Pediatric Hematology and Oncology, Schneider Children's Medical Center of Israel, Petah-Tikva, Israel and Sackler Faculty of Medicine, Tel Aviv University, Israel.
700    1_
$a Colombini, Antonella $u Department of Pediatrics, Ospedale San Gerardo, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.
700    1_
$a Escherich, Gabriele $u University Medical Center Eppendorf, Clinic of Pediatric Hematology and Oncology, Hamburg, Germany.
700    1_
$a Grosjean, Marie $u Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark.
700    1_
$a Krajinovic, Maja $u CHU Sainte-Justine Research Center and Department of Pharmacology, University of Montreal, QC, Canada. Department of Pediatrics, University of Montreal, QC, Canada.
700    1_
$a Larsen, Eric $u Maine Children's Cancer Program, Scarborough, ME, USA.
700    1_
$a Liang, Der-Cherng $u Division of Pediatric Hematology-Oncology, Mackay Memorial Hospital, Taipei, Taiwan.
700    1_
$a Möricke, Anja $u Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Department of Pediatrics, Kiel, Germany.
700    1_
$a Rasmussen, Kirsten K $u Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark.
700    1_
$a Samarasinghe, Sujith $u Great Ormond Street Hospital for Children, London, UK.
700    1_
$a Silverman, Lewis B $u Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
700    1_
$a van der Sluis, Inge M $u Dutch Childhood Oncology Group, The Hague and Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
700    1_
$a Stanulla, Martin $u Department of Pediatric Hematology and Oncology, Hannover Medical School, Germany.
700    1_
$a Tulstrup, Morten $u Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark.
700    1_
$a Yadav, Rachita $u Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark. Molecular Neurogenetics Unit, Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
700    1_
$a Yang, Wenjian $u St. Jude Children's Research Hospital, Department of Pharmaceutical Sciences, Memphis, TN, USA.
700    1_
$a Zapotocka, Ester $u University Hospital Motol, Department of Pediatric Hematology/Oncology, Prague, Czech Republic.
700    1_
$a Gupta, Ramneek $u Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark.
700    1_
$a Schmiegelow, Kjeld $u Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark Kjeld.Schmiegelow@regionh.dk. Institute of Clinical Medicine, University of Copenhagen, Denmark.
710    2_
$a Ponte di Legno toxicity working group
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 104, č. 3 (2019), s. 556-563
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30467200 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214124903 $b ABA008
999    __
$a ok $b bmc $g 1595177 $s 1113534
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 104 $c 3 $d 556-563 $e 20181122 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
GRA    __
$a R00 ES023504 $p NIEHS NIH HHS $2 United States
GRA    __
$a R21 ES025052 $p NIEHS NIH HHS $2 United States
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace